Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease

Zhang, Yaofu; Wang, Junheng; Jiang, Li; Wang, Tongxin; Li, Zhuang; Fu, Xiaozhe; Huang, Weijun; Xiao, Yonghua; Wang, Shidong; Zhao, Jinxi

doi:10.1186/s13098-022-00929-3

Table 1 Baseline Characteristics of included studies in patients with T2DM and CKD

From: Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease

Trial	Study design	Patients enrolled in trials	Patients enrolled in this study	Intervention (mg/day)	Control	Median follow up (years)	Number of patients			Age		Male		BMI(kg/m²)		HbA1C(%)		eGFR (ml/min/1.73 m²)		Duration of diabetes(years)
Trial	Study design	Patients enrolled in trials	Patients enrolled in this study	Intervention (mg/day)	Control	Median follow up (years)	Total	I	C	I	C	I	C	I	C	I	C	I	C	I	C
Finerenone vs placebo
FIDELIO-DKD [9, 10, 30, 31]	RCT	T2D and CKD	T2D and CKD	Finerenone 10/20	Placebo	2.6	6674	2833	3841	65.4 ± 8.9	65.7 ± 9.2	1953	2030	N/A		7.7 ± 1.3	7.7 ± 1.4	44.4 ± 12.5	44.3 ± 12.6	16.6 ± 8.8	16.6 ± 8.8
FIGARO-DKD [30, 32]	RCT	T2D and CKD	T2D and CKD	Finerenone 10/20	Placebo	3.4	7352	3686	3666	64.1 ± 9.8		5107		31.4 ± 6.0		7.7 ± 1.4		67.8 ± 21.7		14.5 ± 8.5
ARTS-DN [33]	RCT	DN	DN	Finerenone 1.25–20	Placebo	0.2	821	727	94	64.33 ± 9.20	63.26 ± 8.68	570	69	31.75 ± 5.57	32.49 ± 5.27	7.6 ± 1.3	7.6 ± 1.3	66.9 ± 21.9	72.2 ± 20.4	N/A
SGLT2i vs placebo
EMPA-REG OUTCOME [13, 34,35,36,37]	RCT	T2D	T2D and CKD	Empagliflozin 10/25	Placebo	3.1	1819	1212	607	67.1 ± 7.6	67.1 ± 8.2	816	418	31.0 ± 5.5	30.9 ± 5.4	8.07 ± 0.86	8.03 ± 0.85	48.4 ± 8.2	48.6 ± 7.8	N/A
EMPA-REG RENAL [38]	RCT	T2D and CKD	T2D and CKD	Empagliflozin 10/25	Placebo	1.0	738	419	319	63.8 ± 8.8	64.1 ± 8.7	249	181	30.9 ± 5.5	30.7 ± 5.5	8.00 ± 0.83	8.10 ± 0.82	55.7 ± 18.8	49.9 ± 18.7	N/A
CREDENCE [15, 39,40,41,42]	RCT	T2D and CKD	T2D and CKD	Canagliflozin 100	Placebo	2.6	4401	2202	2199	62.9 ± 9.2	63.2 ± 9.2	1440	1467	31.4 ± 6.2	31.3 ± 6.2	8.3 ± 1.3	8.3 ± 1.3	56.3 ± 18.2	56.0 ± 18.3	15.5 ± 8.7	16.0 ± 8.6
NCT01064414 [43]	RCT	T2D and CKD	T2D and CKD	Canagliflozin 100/300	Placebo	1.0	269	179	90	68.7 ± 8.2	68.2 ± 8.4	106	57	32.9 ± 6.0	33.1 ± 6.5	7.9 ± 0.9	8.0 ± 0.9	39.1 ± 6.9	40.1 ± 6.8	16.3 ± 7.6	16.4 ± 10.1
DAPA-CKD [17, 44,45,46]	RCT	CKD	T2D and CKD	Dapagliflozin 10	Placebo	2.4	2906	1455	1451	64.1 ± 9.8	64.7 ± 9.5	961	980	30.2 ± 6.2	30.4 ± 6.3	7.8 ± 1.7	7.8 ± 1.6	44.0 ± 12.6	43.6 ± 12.6	13.7	13.8
SCROED [19]	RCT	T2D and CKD	T2D and CKD	Sotagliflozin 400	Placebo	1.3	10,584	5292	5292	69	69	2945	2885	31.9	31.7	8.3	8.3	44.4	44.7	N/A
NCT03242018[47]	RCT	T2D and CKD	T2D and CKD	Sotagliflozin 200/400	Placebo	1.0	277	184	93	67.1 ± 9.8	68.0 ± 8.3	93	42	31.5 ± 5.8	31.7 ± 5.7	8.3 ± 0.9	8.4 ± 1.1	23.9 ± 4.6	24.1 ± 4.4	19.1 ± 9.2	20.7 ± 8.9

I: intervention; C: control; DN: diabetic nephropathy; n/a: not available

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com

Diabetology & Metabolic Syndrome

Contact us